Illumina Inc. logo

Illumina Inc.

ILMN | NASDAQ
Chart Builder DCF Calculator
$227.97
-$8.02 (-3.40%)
Nov 2, 2026, 11:19 AM ET · Market open

Company Profile

Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

Key Executives

Name Position
Jacob Thaysen CEO, President & Director
Ankur Dhingra Chief Financial Officer
Julie Ann Coletti Chief Legal Officer
Mark Field Chief Information Officer
Patricia Leckman Senior Vice President & Chief People Officer
Steven Barnard Chief Technology Officer
Conor Noel McNamara Vice President of Investor Relations
Jakob Wedel Chief Strategy & Corporate Development Officer
Kevin Carl Pegels Chief of Global Operations
Scott Ericksen Vice President & Chief Accounting Officer
Stephanie Campos President

Latest SEC Filings

Date Type Title
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Sep 10, 2026 4 Filing
Sep 09, 2026 4 Filing
Sep 04, 2026 4 Filing
Aug 27, 2026 4 Filing
Aug 21, 2026 4 Filing
Aug 20, 2026 4 Filing
Aug 17, 2026 8-K Current Report
Aug 13, 2026 8-K Current Report
View All SEC Filings ➞
Illumina Inc.
Illumina Inc. logo
Country United States
IPO Date Jul 28, 2000
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 8,600
CEO Jacob Thaysen

Contact Details

5200 Illumina Way San Diego, California 92122 United States

Stock Details

Ticker Symbol ILMN
Exchange NASDAQ
Fiscal Year February - January
Reporting Currency USD
CIK Code 0001110803
CUSIP Number 452327109
ISIN Number US4523271090
SIC Code 3826

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.